1-methyl-4-phenylbutyl methanesulphonate | 63790-07-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-4-phenylbutyl methanesulphonate
• 英文别名: 1-methyl-4-phenylbutyl methanesulfonate；5-phenyl-2-pentyl methanesulfonate；2-methylsulfonyloxy-5-phenylpentane；d,l-5-phenyl-2-pentanol mesylate；5-phenyl-2-pentanol mesylate；dl-5-phenyl-2-pentanol mesylate；5-phenylpentan-2-yl methanesulfonate
• CAS: 63790-07-8
• 化学式: C₁₂H₁₈O₃S
• 分子量: 242.339
• InChiKey: XWGCUHKGFJCGQA-UHFFFAOYSA-N

物化性质

• 沸点：
  395.6±21.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-4-phenylbutyl methanesulphonate 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 、 氨 、 lithium 、 potassium hydride 、 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 乙醚 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 68.58h， 生成
  参考文献：
  名称：

  六氢-6 H-二苯并[ b，d ]吡喃的合成：9-Nor-9β-羟基六氢大麻酚的衍生物

  摘要：

  为了评估大麻素中苯酚功能对于镇痛活性的重要性，制备了一系列新的9-nor-9β-羟基六氢大麻素。合成1 -取代的（H，CH 2 OH，OH，NH 2）6aβ，7,8,9,10,10a α -六氢- 9β羟基-6,6-二甲基-3- [1-甲基描述了来自3，5-二羟基sti，3，3′，5，5′-四羟基sti或1，3，5-三羟基苯的4-苯基丁氧基] -6 H-二苯并[ b，d ]吡喃。通过核磁共振和X射线晶体分析获得相对的立体化学和结构确认。

  DOI：

  10.1002/jhet.5570270312
• 作为产物：
  描述：

  5-苯基戊烷-2-醇 以 吡啶 、 二氯甲烷 为溶剂， 生成 1-methyl-4-phenylbutyl methanesulphonate
  参考文献：
  名称：

  Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one

  摘要：

  本发明涉及新型二氢-［1,2,3］三氮唑-［4,5-d］嘧啶-7-酮，以及它们的制备方法和作为药物的用途，特别是作为cGMP代谢磷酸二酯酶的抑制剂。

  公开号：

  US06458796B1

文献信息

• 9-Hydroxydibenzo[b,d]pyrans and intermediates
  申请人：Pfizer Inc.

  公开号：US04143139A1

  公开（公告）日：1979-03-06

  9-Hydroxydibenzo[b,d]pyrans useful as analgesics, hypotensives, immunosuppressants, tranquilizers; as anti-secretory and anti-anxiety drugs; intermediates therefor and derivatives thereof having the formulae ##STR1## wherein R is hydrogen or alkanoyl having from one to five carbon atoms; R.sub.1 is hydrogen, alkanoyl having from one to five carbon atoms or --CO--(CH.sub.2).sub.P --NR.sub.2 R.sub.3 wherein p is 0 or an integer from 1 to 4; each of R.sub.2 and R.sub.3 when taken individually is hydrogen or alkyl having from one to four carbon atoms; R.sub.2 and R.sub.3 when taken together with the nitrogen to which they are attached form a 5- or 6-membered heterocyclic ring selected from piperidino, pyrrolo, pyrrolidino, morpholino and N-alkylpiperazino having from one to four carbon atoms in the alkyl group; Each of R.sub.4 and R.sub.5 is hydrogen, methyl or ethyl; R.sub.0 is oxo or alkylenedioxy having from two to four carbon atoms; Z is (a) alkylene having from one to nine carbon atoms; (b) --(alk.sub.1).sub.m --X--(alk.sub.2).sub.n --wherein each of (alk.sub.1) and (alk.sub.2) has from 1 to 9 carbon atoms, with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than 9; Each of m and n is 0 or 1; X is O, S, SO or SO.sub.2 ; and W is methyl, phenyl, p-chlorophenyl, p-fluorophenyl, pyridyl, piperidyl, cycloalkyl having from 3 to 7 carbon atoms, or monosubstituted cycloalkyl wherein the substituent is phenyl, p-chlorophenyl or p-fluorophenyl; With the proviso that when W is methyl, Z is --(alk.sub.1).sub.m --X---(alk.sub.2).sub.n --.

  9-羟基二苯并[b,d]吡喃可用作镇痛剂、降压药、免疫抑制剂、镇静剂；作为抗分泌和抗焦虑药物；其中间体和具有以下式的衍生物 ##STR1## 其中R为氢或具有一至五个碳原子的烷酰基；R.sub.1为氢、具有一至五个碳原子的烷酰基或--CO--(CH.sub.2).sub.P --NR.sub.2 R.sub.3，其中p为0或1至4的整数；当单独考虑R.sub.2和R.sub.3时，R.sub.2和R.sub.3分别为氢或具有一至四个碳原子的烷基；当R.sub.2和R.sub.3与它们连接的氮一起形成与哌啶基、吡咯基、吡咯啉基、吗啉基和N-烷基哌嗪基中的一种所选的5-或6-成员杂环环；R.sub.4和R.sub.5中的每一个为氢、甲基或乙基；R.sub.0为氧代或具有二至四个碳原子的烷二氧基；Z为(a)具有一至九个碳原子的烷基；(b) --(alk.sub.1).sub.m --X--(alk.sub.2).sub.n --其中每个(alk.sub.1)和(alk.sub.2)具有1至9个碳原子，但要求(alk.sub.1)加(alk.sub.2)中碳原子的总和不大于9；m和n中的每一个为0或1；X为O、S、SO或SO.sub.2；W为甲基、苯基、对氯苯基、对氟苯基、吡啶基、哌啶基、具有3至7个碳原子的环烷基，或单取代环烷基，其中取代基为苯基、对氯苯基或对氟苯基；但要求当W为甲基时，Z为--(alk.sub.1).sub.m --X---(alk.sub.2).sub.n --。
• Bicyclic benzo fused compounds
  申请人：Pfizer Inc.

  公开号：US04486428A1

  公开（公告）日：1984-12-04

  Bicyclic fused benzenoid compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, where M is O, CH.sub.2 or NR.sub.6 ; R.sub.6 is hydrogen, formyl, carbobenzyloxy or certain carboalkoxyalkyl, alkanoyl, alkyl, aralkyl or aralkylcarbonyl groups; A' is: (1) A where one of A and B is hydrogen such that when A is hydrogen, B is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 1 or 2; when B is hydrogen, A is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 0 or 1, when taken together A and OR.sub.1 form a lactone or certain derivatives thereof; (2) A' is ##STR2## (3) A' is Q.sub.3 ; Q is CO.sub.2 R.sub.7, COR.sub.8, C(OH)R.sub.8 R.sub.9, CN, CONR.sub.12 R.sub.13, CH.sub.2 NR.sub.12 R.sub.13, CH.sub.2 NHCOR.sub.14, CH.sub.2 NHSO.sub.2 R.sub.17 or 5-tetrazoyl; Q.sub.3 is ##STR3## 5-tetrazolyl, CH.sub.2 CONHCOR.sub.7, COOH or certain ester, amide, carboximido or sulfonimido derivatives thereof, CONHOH, CONHCONH.sub.2, or COCH.sub.2 Q.sub.4 where Q.sub.4 is CN or COOH or certain esters thereof; R.sub.1 is hydrogen, benzyl or certain acyl groups; R.sub.4 is hydrogen, certain alkyl or certain aralkyl groups; R.sub.5 is hydrogen or certain alkyl groups; Z is (C.sub.1 -C.sub.9)alkylene, optionally interrupted by O, S, SO or SO.sub.2 ; and W is hydrogen, methyl, certain aryl or cycloalkyl groups; useful in mammals as analgesics, tranquilizers, antiemetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.

  公式为##STR1##的双环融合苯类化合物及其药学上可接受的阳离子和酸盐，其中M为O、CH.sub.2或NR.sub.6；R.sub.6为氢、甲酰基、羟甲基苄氧基或某些羧烷氧基烷基、烷酰基、烷基、芳基烷基或芳基烷基羰基基团；A'为：(1) A，其中A和B中的一个为氢，使得当A为氢时，B为C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q且f为1或2；当B为氢时，A为C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q且f为0或1，当A和OR.sub.1一起形成内酯或其某些衍生物时；(2) A'为##STR2##(3) A'为Q.sub.3；Q为CO.sub.2 R.sub.7、COR.sub.8、C(OH)R.sub.8 R.sub.9、CN、CONR.sub.12 R.sub.13、CH.sub.2 NR.sub.12 R.sub.13、CH.sub.2 NHCOR.sub.14、CH.sub.2 NHSO.sub.2 R.sub.17或5-四唑基；Q.sub.3为##STR3##5-四唑基、CH.sub.2 CONHCOR.sub.7、COOH或其某些酯、酰胺、羧酰亚胺或磺酰亚胺衍生物，CONHOH、CONHCONH.sub.2或COCH.sub.2 Q.sub.4，其中Q.sub.4为CN或COOH或其某些酯；R.sub.1为氢、苄基或某些酰基；R.sub.4为氢、某些烷基或某些芳基烷基；R.sub.5为氢或某些烷基；Z为(C.sub.1-C.sub.9)烷基，可由O、S、SO或SO.sub.2中断；W为氢、甲基、某些芳基或环烷基；在哺乳动物中作为镇痛剂、镇静剂、止吐剂、利尿剂、抗癫痫药、止泻药、镇咳剂、治疗青光眼和其中间体。
• Substituted dodecahydrotriphenylenes,
  申请人：Pfizer Inc.

  公开号：US04473704A1

  公开（公告）日：1984-09-25

  1,2,3,4,4a,4b,5,6,7,8,8a,12b-Dodecahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy or alkoxyalkyl)triphenylenes, 2,3,3a,3b,4,5,6,7,7a,11b-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)-1H-cyclopenta[1]phenanthrenes, 2,3,4,4a,4b,5,6,7,8,8a-decahydro-7-(oxo, hydroxy or amino)-9-hydroxy-11-(alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl)-1H-pyrido[1,2-f]phenanthridines, and 1,2,3,3a,3b,4,5,6,7,7a-decahydro-6-(oxo, hydroxy or amino)-8-hydroxy-10-(alkyl, alkoxy or alkoxyalkyl)pyrrolo[1,2-f]phenanthridines and derivatives are valuable as central nervous system active agents or as intermediates to compounds having such activity.

  1,2,3,4,4a,4b,5,6,7,8,8a,12b-十二氢-7-(氧代、羟基或氨基)-9-羟基-11-(烷基、烷氧基或烷氧基烷基)三苯基烯，2,3,3a,3b,4,5,6,7,7a,11b-十氢-6-(氧代、羟基或氨基)-8-羟基-10-(烷基、烷氧基或烷氧基烷基)-1H-环戊[1]菲，2,3,4,4a,4b,5,6,7,8,8a-十氢-7-(氧代、羟基或氨基)-9-羟基-11-(烷基、烷氧基、烷氧基烷基、芳烷基、芳烷氧基、芳氧基烷基或芳烷氧基烷基)-1H-吡啶并[1,2-f]菲啶，以及1,2,3,3a,3b,4,5,6,7,7a-十氢-6-(氧代、羟基或氨基)-8-羟基-10-(烷基、烷氧基或烷氧基烷基)吡咯并[1,2-f]菲啶及其衍生物，作为中枢神经系统活性剂或作为具有此类活性的化合物的中间体具有重要价值。
• Substituted hexahydropyrrolo[1,2-a]-quinolines, hexahydro-1H-pyrido[1,2-a]-
  申请人：Pfizer Inc.

  公开号：US04476131A1

  公开（公告）日：1984-10-09

  Tricyclic benzo fused compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, wherein n is zero, 1 or 2, and t is 1 or 2; M is CH or N, R.sub.1 is H or certain acyl groups; Q is CO.sub.2 R.sub.4, COR.sub.5, C(OR.sub.7)R.sub.5 R.sub.6, CN, CONR.sub.9 R.sub.10, CH.sub.2 NR.sub.9 R.sub.10, CH.sub.2 NHCOR.sub.11, CH.sub.2 NHSO.sub.2 R.sub.12, 5-tetrazolyl or when n is 1, Q and OR.sub.1 together form a lactone or certain reduced derivatives thereof; and Z is certain alkyl, alkoxy, alkoxyalkyl, aralkyl, aralkoxy, aryloxyalkyl or aralkoxyalkyl groups, are valuable central nervous system active agents, methods for their use, pharmaceutical compositions containing them and certain intermediates therefor.

  三环苯并化合物的结构式为##STR1##及其药学上可接受的阳离子和酸盐，其中n为零、1或2，t为1或2；M为CH或N，R.sub.1为H或特定的酰基；Q为CO.sub.2 R.sub.4、COR.sub.5、C(OR.sub.7)R.sub.5 R.sub.6、CN、CONR.sub.9 R.sub.10、CH.sub.2 NR.sub.9 R.sub.10、CH.sub.2 NHCOR.sub.11、CH.sub.2 NHSO.sub.2 R.sub.12、5-四唑基或当n为1时，Q和OR.sub.1共同形成内酯或其还原衍生物；Z为特定的烷基、烷氧基、烷氧基烷基、芳基烷基、芳基氧基、芳基氧基烷基或芳基烷氧基烷基基团，是有价值的中枢神经系统活性剂，其使用方法、含有它们的药物组合物以及某些中间体。
• 2,10-Disubstituted dibenzo[b,d]pyrans and benzo[c]quinolines
  申请人：Pfizer Inc.

  公开号：US04206225A1

  公开（公告）日：1980-06-03

  A compound of the formula ##STR1## wherein Q is CH.sub.2, C.dbd.O, CHOH or CHCH.sub.2 OH; M is O or NR.sub.6 ; where R.sub.6 is hydrogen, or certain alkyl, aralkyl, acyl or carboalkoxy substituted alkyl groups; R.sub.1 is hydrogen, or certain alkanoyl or amino substituted alkanoyl groups; R.sub.4 and R.sub.5 are each hydrogen or alkyl having from 1 to 4 carbon atoms; Z is alkylene having from 1 to 9 carbon atoms or --(alk.sub.1)--X--(alk.sub.2).sub.n -- where (alk.sub.1) and (alk.sub.2) are certain alkylene groups and X is O, S, SO or SO.sub.2 ; W is a methyl, phenyl, substituted phenyl, pyridyl, piperidyl, cycloalkyl or substituted cycloalkyl group and the pharmaceutically acceptable and addition salts of said compounds having a basic nitrogen atoms. Said compounds are useful as analgesics and as intermediates therefore.

  式为##STR1##的化合物，其中Q为CH.sub.2、C.dbd.O、CHOH或CHCH.sub.2 OH；M为O或NR.sub.6；其中R.sub.6为氢，或某些烷基、芳基烷基、酰基或羰基烷基取代基；R.sub.1为氢，或某些烷酰基或氨基取代的烷酰基取代基；R.sub.4和R.sub.5分别为氢或含有1至4个碳原子的烷基；Z为含有1至9个碳原子的烷基或--(alk.sub.1)--X--(alk.sub.2).sub.n--，其中(alk.sub.1)和(alk.sub.2)为某些烷基基团，X为O、S、SO或SO.sub.2；W为甲基、苯基、取代苯基、吡啶基、哌啶基、环烷基或取代环烷基基团，以及具有含有碱性氮原子的药用可接受的所述化合物的加合盐。所述化合物可用作镇痛剂和其中间体。